Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (GB:0A88)
LSE:0A88
Holding GB:0A88?
Track your performance easily
0A88 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.94 - $57.64
Previous Close$14.15
Volume1.07K
Average Volume (3M)5.16K
Market Cap
$1.65B
Enterprise Value$1.34B
Total Cash (Recent Filing)$398.16M
Total Debt (Recent Filing)$85.88M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Feb 12, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding121,054,448
10 Day Avg. Volume1,330
30 Day Avg. Volume5,162
Standard Deviation0.17
R-Squared0.10
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)2.39
Price to Sales (P/S)2.62
Price to Cash Flow (P/CF)19.00
P/FCF Ratio23.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda-10.19
Forecast
1Y Price Target
$20.40Price Target Upside44.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
10x Genomics News
PremiumCompany Announcements
10x Genomics Reports Mixed Q3 2024 Results
PremiumCompany Announcements
10x Genomics Navigates Revenue Dip with New LaunchesBulls Say, Bears Say
Bulls Say
Financial PerformanceServices revenue showed a strong growth of 48% year over year, exceeding market expectations.
Market LeadershipTXG's single-cell portfolio and spatial products remain number one in the market despite disruptions.
Product DemandSpatial consumable revenue increased by 111% driven by demand for new products like Visium HD and Xenium Prime 5K.
Bears Say
Guidance ReductionThe company lowered its 2024 revenue guidance, reflecting soft 4Q performance.
Revenue Shortfall3Q revenue of $151.7M came in significantly below expectations due to cautious customer spending and commercial restructuring initiatives.
Sales Force DisruptionA major sales force overhaul has caused disruption, with 40% of US accounts having a new sales representative and 44 open commercial/sales positions.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.08% Insiders
27.76% Mutual Funds
37.86% Other Institutional Investors
10.28% Public Companies and
Individual Investors
0A88 FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest share price was $12.94 and its highest was $57.64 in the past 12 months.
What is 10x Genomics Inc’s market cap?
Currently, no data Available
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Feb 12, 2025 which is in 52 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Oct 29, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.029.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -$0.31.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 106,997,610 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went up 4.642%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Among the largest hedge funds holding 10x Genomics Inc’s share is ARK Investment Management LLC. It holds 10x Genomics Inc’s shares valued at 243M.
---
10x Genomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.40 (44.20% Upside)
$20.40 (44.20% Upside)
Blogger Sentiment
Bearish
GB:0A88 Sentiment 67%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $171.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.26%
12-Months-Change
Fundamentals
Return on Equity
-24.87%
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
0A88 Company Deck
---
0A88 Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Negative
While the company made strides in improving gross margins and saw significant growth in spatial consumables, it faced challenges with declining overall revenue, sales restructuring disruptions, and cautious customer spending. The sentiment is tempered by the strong spatial consumables performance but overshadowed by the revenue decline and sales restructuring issues.Read More>---
0A88 Revenue Breakdown
77.51% Consumables
19.96% Instruments
2.54% Services
---
0A88 Stock 12 Month Forecast
Average Price Target
$20.40
▲(44.20% Upside)
Technical Analysis
10x Genomics
―
Pacific Biosciences
―
Twist Bioscience
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 0A88
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+5.90%
reiterated a buy rating 2 months ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +5.90% per trade.
---